Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 4/2015

01.04.2015 | Original Article

Synthesis and biological evaluation of geldanamycin analogs against human cancer cells

verfasst von: Yan-ping Li, Jin-jing Chen, Jia-jia Shen, Jing Cui, Lin-zhuan Wu, Zhen Wang, Zhuo-rong Li

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To find novel potential and less toxic benquinone anamycin heat shock protein 90 (Hsp90) inhibitors as anticancer agents, a limited series of 17-substituted or 17,19-disubstituted 17-demethoxygeldanamycin analogs were synthesized and tested for anti-proliferation activity against human cancer cells. Liver toxicity was also tested in vivo.

Methods

Five 17-alkylamino-17-demethoxygeldanamycins and two 17-alkylamino-19-methylthio-17-demethoxygeldanamycins were synthesized from geldanamycin (GA) and 19-methylthiogeldanamycin (19-S(methyl)-GA), respectively. Anti-proliferation activities of the GA analogs were determined in MCF7, HeLa, HCT116 and HepG2 cells using the MTT method. Western blot and cell cycle analyses were performed for mechanistic study. The growth inhibition effect of potential geldanamycins was also investigated in normal Buffalo rat liver (BRL) cells. In vivo liver toxicity was tested in Institute of Cancer Research (ICR) mice by tail vein injection of the tested compounds.

Results

Most of the 17-alkylaminogeldanamycins exhibited obvious growth inhibition effects on multiple human cancer cell lines. The anti-proliferation activity of 19-methylthio-substituted geldanamycins was significantly lower compared with no 19-substitution geldanamycins in all tested cancer cells. The compound 1b (17-[2-(piperidinyl-1′-yl)-ethylamino]-17-demethoxygeldanamycin) exhibited the highest anti-proliferation activity in MCF7, HeLa and HCT116 cells, which was much more effective than GA and the developing Hsp90 inhibitor 17-AAG (17-allylamino-17-demethoxygeldanamycin). Meanwhile, compound 1b exhibited weaker growth inhibition effect on BRL cell line than GA and 17-AAG. 1b induced cell cycle arrest at the G2/M phase in MCF7 cells. Cleavage of PARP associated with apoptosis and degradation of the Hsp90 client protein Akt and Her2 was also induced by treatment of 1b in HeLa and MCF7 cell lines. In spite of the relatively weaker activity of 1b compared with GA and 17-AAG against HepG2 cells, 1b was further identified with lower hepatotoxicity than GA in vivo.

Conclusion

Compound 1b is regarded as a new potential Hsp90 inhibitor with low hepatotoxicity for further study.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Csermely P, Schnaider T, Soti C, Prohaszka Z, Nardai G (1998) The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther 79(2):129–168CrossRefPubMed Csermely P, Schnaider T, Soti C, Prohaszka Z, Nardai G (1998) The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther 79(2):129–168CrossRefPubMed
8.
Zurück zum Zitat Garcia-Carbonero R, Carnero A, Paz-Ares L (2013) Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol 14(9):E358–E369CrossRefPubMed Garcia-Carbonero R, Carnero A, Paz-Ares L (2013) Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol 14(9):E358–E369CrossRefPubMed
11.
12.
14.
Zurück zum Zitat Tian ZQ, Wang Z, MacMillan KS, Zhou Y, Carreras CW, Mueller T, Myles DC, Liu Y (2009) Potent cytotoxic C-11 modified geldanamycin analogues. J Med Chem 52(10):3265–3273. doi:10.1021/jm900098v CrossRefPubMed Tian ZQ, Wang Z, MacMillan KS, Zhou Y, Carreras CW, Mueller T, Myles DC, Liu Y (2009) Potent cytotoxic C-11 modified geldanamycin analogues. J Med Chem 52(10):3265–3273. doi:10.​1021/​jm900098v CrossRefPubMed
15.
16.
Zurück zum Zitat Heath EI, Hillman DW, Vaishampayan U, Sheng SJ, Sarkar F, Harper F, Gaskins M, Pitot HC, Tan W, Ivy SP, Pili R, Carducci MA, Erlichman C, Liu G (2008) A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res 14(23):7940–7946. doi:10.1158/1078-0432.Ccr-08-0221 CrossRefPubMedCentralPubMed Heath EI, Hillman DW, Vaishampayan U, Sheng SJ, Sarkar F, Harper F, Gaskins M, Pitot HC, Tan W, Ivy SP, Pili R, Carducci MA, Erlichman C, Liu G (2008) A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res 14(23):7940–7946. doi:10.​1158/​1078-0432.​Ccr-08-0221 CrossRefPubMedCentralPubMed
17.
Zurück zum Zitat Burris HA 3rd, Berman D, Murthy B, Jones S (2011) Tanespimycin pharmacokinetics: a randomized dose-escalation crossover phase 1 study of two formulations. Cancer Chemother Pharmacol 67(5):1045–1054. doi:10.1007/s00280-010-1398-6 CrossRefPubMed Burris HA 3rd, Berman D, Murthy B, Jones S (2011) Tanespimycin pharmacokinetics: a randomized dose-escalation crossover phase 1 study of two formulations. Cancer Chemother Pharmacol 67(5):1045–1054. doi:10.​1007/​s00280-010-1398-6 CrossRefPubMed
18.
Zurück zum Zitat Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, Arkenau HT, Moreno-Farre J, Banerji U, Roels B, Peachey H, Aherne W, de Bono JS, Raynaud F, Workman P, Judson I (2011) A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res 17(6):1561–1570. doi:10.1158/1078-0432.CCR-10-1927 CrossRefPubMedCentralPubMed Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, Arkenau HT, Moreno-Farre J, Banerji U, Roels B, Peachey H, Aherne W, de Bono JS, Raynaud F, Workman P, Judson I (2011) A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res 17(6):1561–1570. doi:10.​1158/​1078-0432.​CCR-10-1927 CrossRefPubMedCentralPubMed
19.
Zurück zum Zitat Sequist LV, Gettinger S, Senzer NN, Martins RG, Janne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R, Hafeez N, Sweeney J, Walker JR, Fritz C, Ross RW, Grayzel D, Engelman JA, Borger DR, Paez G, Natale R (2010) Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 28(33):4953–4960. doi:10.1200/JCO.2010.30.8338 CrossRefPubMed Sequist LV, Gettinger S, Senzer NN, Martins RG, Janne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R, Hafeez N, Sweeney J, Walker JR, Fritz C, Ross RW, Grayzel D, Engelman JA, Borger DR, Paez G, Natale R (2010) Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 28(33):4953–4960. doi:10.​1200/​JCO.​2010.​30.​8338 CrossRefPubMed
20.
Zurück zum Zitat Kitson RRA, Chang CH, Xiong R, Williams HEL, Davis AL, Lewis W, Dehn DL, Siegel D, Roe SM, Prodromou C, Ross D, Moody CJ (2013) Synthesis of 19-substituted geldanamycins with altered conformations and their binding to heat shock protein Hsp90. Nat Chem 5(4):307–314. doi:10.1038/Nchem.1596 CrossRefPubMed Kitson RRA, Chang CH, Xiong R, Williams HEL, Davis AL, Lewis W, Dehn DL, Siegel D, Roe SM, Prodromou C, Ross D, Moody CJ (2013) Synthesis of 19-substituted geldanamycins with altered conformations and their binding to heat shock protein Hsp90. Nat Chem 5(4):307–314. doi:10.​1038/​Nchem.​1596 CrossRefPubMed
21.
Zurück zum Zitat Li YP, Shan GZ, Peng ZG, Zhu JH, Meng S, Zhang T, Gao LY, Tao PZ, Gao RM, Li YH, Jiang JD, Li ZR (2010) Synthesis and biological evaluation of heat-shock protein 90 inhibitors: geldanamycin derivatives with broad antiviral activities. Antivir Chem Chemother 20(6):259–268. doi:10.3851/IMP1631 PubMed Li YP, Shan GZ, Peng ZG, Zhu JH, Meng S, Zhang T, Gao LY, Tao PZ, Gao RM, Li YH, Jiang JD, Li ZR (2010) Synthesis and biological evaluation of heat-shock protein 90 inhibitors: geldanamycin derivatives with broad antiviral activities. Antivir Chem Chemother 20(6):259–268. doi:10.​3851/​IMP1631 PubMed
22.
Zurück zum Zitat Shan GZ, Peng ZG, Li YH, Li D, Li YP, Meng SA, Gao LY, Jiang JD, Li ZR (2011) A novel class of geldanamycin derivatives as HCV replication inhibitors targeting on Hsp90: synthesis, structure-activity relationships and anti-HCV activity in GS4.3 replicon cells. J Antibiot 64(2):177–182. doi:10.1038/Ja.2010.161 CrossRefPubMed Shan GZ, Peng ZG, Li YH, Li D, Li YP, Meng SA, Gao LY, Jiang JD, Li ZR (2011) A novel class of geldanamycin derivatives as HCV replication inhibitors targeting on Hsp90: synthesis, structure-activity relationships and anti-HCV activity in GS4.3 replicon cells. J Antibiot 64(2):177–182. doi:10.​1038/​Ja.​2010.​161 CrossRefPubMed
23.
Zurück zum Zitat Liu X, Li J, Ni S, Wu L, Wang H, Lin L, He W, Wang Y (2011) A pair of sulfur-containing geldanamycin analogs, 19-S-methylgeldanamycin and 4,5-dihydro- 19-S-methylgeldanamycin, from Streptomyces hygroscopicus 17997. J Antibiot (Tokyo) 64(7):519–522. doi:10.1038/ja.2011.39 CrossRef Liu X, Li J, Ni S, Wu L, Wang H, Lin L, He W, Wang Y (2011) A pair of sulfur-containing geldanamycin analogs, 19-S-methylgeldanamycin and 4,5-dihydro- 19-S-methylgeldanamycin, from Streptomyces hygroscopicus 17997. J Antibiot (Tokyo) 64(7):519–522. doi:10.​1038/​ja.​2011.​39 CrossRef
24.
Zurück zum Zitat Grem JL, Morrison G, Guo XD, Agnew E, Takimoto CH, Thomas R, Szabo E, Grochow L, Grollman F, Hamilton JM, Neckers L, Wilson RH (2005) Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 23(9):1885–1893. doi:10.1200/JCO.2005.12.085 CrossRefPubMed Grem JL, Morrison G, Guo XD, Agnew E, Takimoto CH, Thomas R, Szabo E, Grochow L, Grollman F, Hamilton JM, Neckers L, Wilson RH (2005) Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 23(9):1885–1893. doi:10.​1200/​JCO.​2005.​12.​085 CrossRefPubMed
25.
Zurück zum Zitat Li ZY, Jia LJ, Wang JF, Wu XK, Hao HL, Xu HJ, Wu YF, Shi GW, Lu CH, Shen YM (2014) Design, synthesis and biological evaluation of 17-arylmethylamine-17-demethoxygeldanamycin derivatives as potent Hsp90 inhibitors. Eur J Med Chem 85 (1768–3254 (Electronic)):359–370. doi:10.1016/J.Ejmech.2014.07.101 Li ZY, Jia LJ, Wang JF, Wu XK, Hao HL, Xu HJ, Wu YF, Shi GW, Lu CH, Shen YM (2014) Design, synthesis and biological evaluation of 17-arylmethylamine-17-demethoxygeldanamycin derivatives as potent Hsp90 inhibitors. Eur J Med Chem 85 (1768–3254 (Electronic)):359–370. doi:10.​1016/​J.​Ejmech.​2014.​07.​101
26.
28.
Zurück zum Zitat Cysyk RL, Parker RJ, Barchi JJ Jr, Steeg PS, Hartman NR, Strong JM (2006) Reaction of geldanamycin and C17-substituted analogues with glutathione: product identifications and pharmacological implications. Chem Res Toxicol 19(3):376–381. doi:10.1021/tx050237e CrossRefPubMed Cysyk RL, Parker RJ, Barchi JJ Jr, Steeg PS, Hartman NR, Strong JM (2006) Reaction of geldanamycin and C17-substituted analogues with glutathione: product identifications and pharmacological implications. Chem Res Toxicol 19(3):376–381. doi:10.​1021/​tx050237e CrossRefPubMed
30.
Zurück zum Zitat Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, Ross D (2005) Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res 65(21):10006–10015. doi:10.1158/0008-5472.CAN-05-2029 CrossRefPubMed Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, Ross D (2005) Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res 65(21):10006–10015. doi:10.​1158/​0008-5472.​CAN-05-2029 CrossRefPubMed
31.
Zurück zum Zitat Li YP, Gao LY, Li KT, Meng S, Zhu JH, Li D, Jin J, Shan GZ, Li ZR (2013) LC-MS/MS method for determination of geldanamycin derivative GM-AMPL in rat plasma to support preclinical development. J Chromatogr B Analyt Technol Biomed Life Sci 912 (1873–376X (Electronic)):43-49. doi:10.1016/j.jchromb.2012.09.002 Li YP, Gao LY, Li KT, Meng S, Zhu JH, Li D, Jin J, Shan GZ, Li ZR (2013) LC-MS/MS method for determination of geldanamycin derivative GM-AMPL in rat plasma to support preclinical development. J Chromatogr B Analyt Technol Biomed Life Sci 912 (1873–376X (Electronic)):43-49. doi:10.​1016/​j.​jchromb.​2012.​09.​002
32.
Zurück zum Zitat Senju M, Sueoka N, Sato A, Iwanaga K, Sakao Y, Tomimitsu S, Tominaga M, Irie K, Hayashi S, Sueoka E (2006) Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines. J Cancer Res Clin Oncol 132(3):150–158. doi:10.1007/s00432-005-0047-7 CrossRefPubMed Senju M, Sueoka N, Sato A, Iwanaga K, Sakao Y, Tomimitsu S, Tominaga M, Irie K, Hayashi S, Sueoka E (2006) Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines. J Cancer Res Clin Oncol 132(3):150–158. doi:10.​1007/​s00432-005-0047-7 CrossRefPubMed
34.
Zurück zum Zitat Lai CH, Park KS, Lee DH, Alberobello AT, Raffeld M, Pierobon M, Pin E, Petricoin Iii EF, Wang Y, Giaccone G (2014) HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer. Oncogene 33(40):4867–4876. doi:10.1038/onc.2013.439 CrossRefPubMed Lai CH, Park KS, Lee DH, Alberobello AT, Raffeld M, Pierobon M, Pin E, Petricoin Iii EF, Wang Y, Giaccone G (2014) HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer. Oncogene 33(40):4867–4876. doi:10.​1038/​onc.​2013.​439 CrossRefPubMed
35.
Zurück zum Zitat Boridy S, Le PU, Petrecca K, Maysinger D (2014) Celastrol targets proteostasis and acts synergistically with a heat-shock protein 90 inhibitor to kill human glioblastoma cells. Cell Death Dis 5 (2041-4889 (Electronic)):e1216. doi:10.1038/cddis.2014.182 Boridy S, Le PU, Petrecca K, Maysinger D (2014) Celastrol targets proteostasis and acts synergistically with a heat-shock protein 90 inhibitor to kill human glioblastoma cells. Cell Death Dis 5 (2041-4889 (Electronic)):e1216. doi:10.​1038/​cddis.​2014.​182
36.
Zurück zum Zitat Ui T, Morishima K, Saito S, Sakuma Y, Fujii H, Hosoya Y, Ishikawa S, Aburatani H, Fukayama M, Niki T, Yasuda Y (2014) The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway. Oncol Rep 31(2):619–624. doi:10.3892/or.2013.2899 PubMed Ui T, Morishima K, Saito S, Sakuma Y, Fujii H, Hosoya Y, Ishikawa S, Aburatani H, Fukayama M, Niki T, Yasuda Y (2014) The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway. Oncol Rep 31(2):619–624. doi:10.​3892/​or.​2013.​2899 PubMed
37.
Metadaten
Titel
Synthesis and biological evaluation of geldanamycin analogs against human cancer cells
verfasst von
Yan-ping Li
Jin-jing Chen
Jia-jia Shen
Jing Cui
Lin-zhuan Wu
Zhen Wang
Zhuo-rong Li
Publikationsdatum
01.04.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 4/2015
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-015-2696-9

Weitere Artikel der Ausgabe 4/2015

Cancer Chemotherapy and Pharmacology 4/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.